Random gunfire is not currently considered a violent crime, with DPD rating it as a priority 3 call, which is considered a ...
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
The U.S. Department of Energy (DOE) has announced it will preserve nearly $5 billion in funding for five hydrogen hubs across ...
Barbara Burtness, MD, discusses the latest highlights from the AACR Annual Meeting 2026 that took place April 17-22.
David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck KGaA, Darmstadt, Germany ...
A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...
Bristol-Myers Squibb's growth portfolio nears 60% of total revenues, growing 16% YoY, effectively offsetting patent cliff ...
Sleep Apnea Solution author Dylan Petkus, MD, has developed a non-device, behavior-based alternative approach to sleep apnea.
Purdue is a program that utilizes redshirt years to its advantage. Would the NCAA's proposed five-for-five eligibility help ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...
Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results